vTv Therapeutics (NASDAQ:VTVT – Get Free Report) and Sweet Earth (OTCMKTS:SEHCF – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.
Earnings & Valuation
This table compares vTv Therapeutics and Sweet Earth”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| vTv Therapeutics | $1.02 million | 130.99 | -$26.97 million | ($1.06) | -31.99 |
| Sweet Earth | N/A | N/A | N/A | N/A | N/A |
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for vTv Therapeutics and Sweet Earth, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| vTv Therapeutics | 2 | 0 | 6 | 0 | 2.50 |
| Sweet Earth | 0 | 0 | 0 | 0 | 0.00 |
vTv Therapeutics presently has a consensus target price of $55.83, suggesting a potential upside of 64.65%. Given vTv Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe vTv Therapeutics is more favorable than Sweet Earth.
Profitability
This table compares vTv Therapeutics and Sweet Earth’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| vTv Therapeutics | N/A | -6.27% | -5.06% |
| Sweet Earth | N/A | N/A | N/A |
Insider & Institutional Ownership
17.5% of vTv Therapeutics shares are owned by institutional investors. 6.0% of vTv Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
vTv Therapeutics beats Sweet Earth on 6 of the 8 factors compared between the two stocks.
About vTv Therapeutics
vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.
About Sweet Earth
Sweet Earth Holdings Corporation cultivates, processes, and sells hemp cannabidiol (CBD) products in the United States and internationally. The company offers CBD and hemp infused facial products, including CBD hydration creams, oat and honey cleansers, and soothing CBD lip balms; and botanicals and essential oils, such as balancing CBD jasmine oils, soothing CBD bath salt soaks, invigorating CBD neem and turmeric scrubs, and aloe-infused CBD hand sanitizers for body and skin care. It also provides beard and face care products for men comprising CBD face cleansers, shaving creams, aftershave creams, beard and face oils, and styling balms; hemp products; CBD pre-rolls; and CBD dog treats consisting of garbanzo, flour, potato flakes, cheddar cheese, full spectrum hemp oil, natural beef flavor, MCT coconut oil, and mixed tocopherols. The company is based in Vancouver, Canada.
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
